Full-Time
Oncology Account Manager
Syndax
201-500 employees
Biopharmaceutical company developing oncology therapies
Compensation Overview
$215k - $230k/yr
Detroit, MI, USA
In Person
 Sales & Account Management |
|---|
- BA/BS or healthcare equivalent degree
- Minimum 5+ years of previous pharmaceutical, biotech, and/or medical sales experience with a strong preference for Oncology/Hematology
- Knowledge of the pharmaceutical marketplace and deep understanding of industry and broader trends in the healthcare landscape
- Collaborative and organizationally savvy team player with a history of success in a matrixed setting
- Strong negotiation, partnering, and influencing skills
- Demonstrated ability to effectively manage business relationships with external strategic partners
- Prior experience working in large accounts and/or hospitals required
- Expert at navigating complexities and removing barriers to advance corporate objectives in service of patients, caregivers, and HCPs
- Successful product launch experience required
- Must possess a valid driver's license and have reliable access to a personal vehicle for travel as required by the role
- Travel: Ability to travel on a frequent overnight basis, with occasional weekend travel, depending on business needs
- Holistically support and manage territory accounts by creating relationships with physicians, allied healthcare professionals (Advanced Practitioners, Nurses, Pharmacists), and business stakeholders (CFOs, Office Practice Managers, Billers, etc.)
- Maintain a uniquely deep and nuanced understanding of territory, including Opinion Leaders (OL) and other influencers, treatment and utilization trends, payer and reimbursement dynamics, and competitive opportunities and challenges.
- Analyze business performance: Create and execute a comprehensive territory plan. This includes developing unique account plans, delivering branded sales messages, executing planned programs, scheduling and following up with medical education programs, and achieving or exceeding sales targets.
- Demonstrate clinical/disease/product expertise and deliver strategic customer education.
- Work closely with multiple Syndax internal stakeholders inside and outside the commercial organization to ensure strategic alignment and execution of key strategies/tactics to advance overall business objectives.
- Implement processes for appropriate patient identification and treatment management.
- Utilize internal relationships and develop external relationships with account stakeholders, including, but limited to, HCPs and advanced practice providers, to service and manage accounts.
- Have passion for our products through the entire sales cycle while always building our brand and never losing sight of how we serve humans.
- Leverage your passion for Oncology/disease state awareness, industry, regulatory, and competitive changes to deliver agreed results.
- Ideal candidates have strong clinical selling skills, excellent communication/presentation skills, effective working in teams and self-starters, as well as strategic and forward thinking
- Prior pharma/biotech start-up experience preferred
- Technologically savvy and committed to leveraging data and advanced analytics daily to drive business results
Syndax Pharmaceuticals focuses on developing therapies for cancer. Its work centers on researching, testing through clinical trials, and commercializing cancer drugs, with an emphasis on difficult-to-treat cancers such as HR+ HER2- breast cancer. The company’s lead asset is Entinostat, which is being studied in combination with Exemestane for HR+ HER2- breast cancer; results from these trials will influence its growth and market position. Syndax funds its R&D and operations through capital raises and potential licensing or partnerships, and generates revenue by selling approved medicines. Its goal is to bring new cancer treatments to patients who have limited options by advancing promising oncology therapies and securing successful regulatory approvals and partnerships to scale those therapies.
Company Size
201-500
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2005
Your Connections
People at Syndax who can refer or advise you
Simplify's Take
What believers are saying
- Revuforj real-world data supports frontline and post-transplant expansion, potentially doubling label scope and peak sales beyond initial approval.
- Niktimvo Phase 2 readouts in IPF and chronic GVHD expected Q4 2026, opening new multisystem indications with large market opportunities.
- $352M cash runway plus $64.9M Q1 2026 revenue (224% YoY growth) supports path to profitability without immediate dilution.
What critics are saying
- Boxed safety warnings for fatal differentiation syndrome and QTc prolongation drive 4% fatality rate, triggering discontinuations, liability, and slower AML uptake in 6-18 months.
- Transplant-driven revenue leakage from paused therapy lumps sales, as seen in Q1 2026, risking volatile revenue and delayed physician prescribing within 6-12 months.
- Frontline AML expansion failure would collapse main upside case, given 35-55% probability of weak 2026 readouts destroying label expansion odds and peak sales.
What makes Syndax unique
- Only FDA-approved menin inhibitor for both KMT2A-rearranged and NPM1-mutated acute leukemia, enabling broader commercial base than single-indication drugs.
- Dual monetization from Revuforj sales and 50% Niktimvo profit share, creating multiple revenue engines beyond reliance on one asset.
- Strong clinical credibility with 97% composite complete remission in frontline AML and 90% two-year survival post-transplant, outperforming historical benchmarks.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 11%2 year growth
↑ 17%DAFNA Capital Management sold 222,847 shares of Syndax Pharmaceuticals in the fourth quarter of 2025, with an estimated transaction value of $3.89 million, according to a 17 February 2026 SEC filing. The sale reduced Syndax's weighting in DAFNA's portfolio from 1.90% to 1.36% of its $430.52 million in reportable assets. Despite the trim, Syndax shares have surged 72% over the past year to $24.23, significantly outperforming the S&P 500's 15% gain. Syndax, a clinical-stage biopharmaceutical company focused on oncology therapies, generated $172.4 million in revenue over the trailing twelve months whilst posting a net loss of $285.4 million. The company is developing treatments including SNDX-5613 for acute myeloid leukaemia and axatilimab for chronic graft versus host disease.
Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals valued at approximately $8.18 million during the fourth quarter of 2025, according to a Securities and Exchange Commission filing dated 17 February 2026. Despite the sale, the fund retained a significant stake, with Syndax remaining its third-largest holding at 10.81% of reportable assets. Syndax shares have surged 72% over the past year, reaching $24.23, substantially outperforming the S&P 500's 15% gain. The clinical-stage biotechnology company generated $172 million in revenue last year, driven by uptake of recently launched therapies including Revuforj and its Niktimvo collaboration. However, the company posted a $285 million net loss for the year amid elevated research and development costs. Kynam's partial sale appears to be portfolio rebalancing rather than a loss of confidence in the biotech firm.
Sphera Funds Management purchased 374,847 shares of Syndax Pharmaceuticals in the fourth quarter, an estimated $6.54 million investment based on quarterly average pricing. The acquisition brought Sphera's total holding to 762,563 shares valued at $16.02 million, representing approximately 3% of its assets under management. Syndax Pharmaceuticals, a biotechnology company developing cancer therapies, reported $172.4 million in revenue for 2025, up sharply from $23.7 million the previous year. The growth was driven by two approved therapies: Revuforj, which generated $124.8 million in full-year revenue, and Niktimvo, developed with Incyte, which delivered $151.6 million in net sales. Shares have surged 83% over the past year, significantly outperforming the S&P 500's roughly 20% gain.
Syndax Pharmaceuticals reported strong commercial performance for its two flagship cancer drugs at the Guggenheim biotech conference on 15 February. Chief Executive Officer Michael Metzger said the company started 2026 on solid footing with significant progress on clinical milestones. Revuforj generated $125 million in net sales during the first 11 months, driven by penetration in acute myeloid leukaemia treatment. Niktimvo achieved $152 million in sales, with both products showing quarter-over-quarter growth. The company sees significant opportunity in chronic graft-versus-host disease treatment, targeting up to 17,000 patients. Syndax estimates potential third-line plus sales of up to $1 billion. The company has a strategic collaboration with Incyte to co-promote Niktimvo.
Syndax Pharmaceuticals reported Revuforj generated $124.8 million in net revenue during 2025, its first full year on the market. Fourth-quarter revenue reached $44.2 million, driven by growth in KMT2A-rearranged acute myeloid leukaemia and increasing uptake in NPM1-mutated AML following an expanded FDA label in late October. Chief Commercial Officer Steve Closter said the company is approaching 50% penetration of the KMT2A incident population. The NPM1 indication triples the addressable patient population to approximately 3,000 patients annually, with formulary coverage complete at major payers within four months of approval. Management indicated NPM1 patients represented roughly 30% of new starts in the fourth quarter and expect the indication to grow towards a 50/50 split with KMT2A given the larger patient population.